#1 Clinical Trials Search in Europe

Rivaroxaban

This article examines the use of rivaroxaban (Xarelto) in various clinical trials. Rivaroxaban is an anticoagulant medication used to prevent blood clots and reduce the risk of stroke in patients with certain heart conditions. The trials discussed here investigate rivaroxaban’s efficacy, safety, and optimal dosing for conditions like atrial fibrillation, peripheral artery disease, and heparin-induced thrombocytopenia.

Table of Contents

What is Rivaroxaban?

Rivaroxaban, also known by its brand name Xarelto, is a type of medication called a direct oral anticoagulant (DOAC)[1]. It’s often referred to as a “blood thinner,” although it doesn’t actually thin your blood. Instead, it helps prevent blood clots from forming or growing larger[2].

What Conditions Does Rivaroxaban Treat?

Rivaroxaban is used to treat and prevent several conditions related to blood clots:

  • Atrial Fibrillation: This is an irregular heart rhythm that can increase the risk of stroke. Rivaroxaban helps prevent strokes in people with non-valvular atrial fibrillation[2].
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): These are types of blood clots that can form in the legs (DVT) and travel to the lungs (PE). Rivaroxaban can both treat existing clots and prevent new ones[2].
  • Prevention of Blood Clots After Surgery: Rivaroxaban may be used to prevent blood clots in people who have had hip or knee replacement surgery[1].
  • Peripheral Arterial Disease (PAD): This condition affects blood flow in the arteries, particularly in the legs. Rivaroxaban may help prevent serious complications in people with PAD[6].

How Does Rivaroxaban Work?

Rivaroxaban works by directly inhibiting a protein in your blood called Factor Xa. This protein plays a crucial role in the blood clotting process. By blocking Factor Xa, Rivaroxaban interrupts the chain of events that leads to blood clot formation[1].

This mechanism of action is different from older blood thinners like warfarin, which work by interfering with vitamin K in your body. Because of this, Rivaroxaban doesn’t require regular blood tests to monitor its effectiveness, unlike warfarin[8].

Dosage and Administration

Rivaroxaban is taken orally, usually once or twice daily depending on the condition being treated and other factors. The dosage can vary:

  • For atrial fibrillation, the typical dose is 20 mg once daily[7].
  • A lower dose of 15 mg once daily may be used for people with reduced kidney function[7].
  • For treatment of DVT or PE, a higher initial dose (15 mg twice daily) may be used for the first few weeks, followed by a lower maintenance dose[9].

It’s crucial to take Rivaroxaban exactly as prescribed by your doctor. Don’t stop taking it without consulting your healthcare provider, as this could increase your risk of blood clots[1].

Effectiveness of Rivaroxaban

Several studies have shown Rivaroxaban to be effective in preventing strokes in people with atrial fibrillation and in treating and preventing blood clots in other conditions. For example:

  • In patients with atrial fibrillation, Rivaroxaban has been shown to be at least as effective as warfarin in preventing strokes, with potentially fewer bleeding complications[8].
  • For treatment of DVT and PE, Rivaroxaban has demonstrated similar efficacy to traditional treatment with injectable blood thinners followed by warfarin[1].
  • In patients with peripheral arterial disease, Rivaroxaban (when combined with aspirin) may help reduce the risk of heart attacks, strokes, and other cardiovascular events[6].

Potential Side Effects and Safety Concerns

Like all medications, Rivaroxaban can cause side effects. The most common and serious side effect is bleeding. This can include:

  • Minor bleeding, such as nosebleeds or bleeding gums
  • More serious bleeding, such as internal bleeding or bleeding in the brain (which is rare but can be life-threatening)[6]

Other potential side effects may include:

  • Back pain
  • Stomach pain
  • Itching
  • Muscle spasms[3]

It’s important to inform your doctor immediately if you experience any unusual bleeding or symptoms. Also, make sure all your healthcare providers know you’re taking Rivaroxaban before any medical procedures or starting new medications[1].

Ongoing Research and Future Perspectives

Research on Rivaroxaban is ongoing, with several studies exploring its use in various conditions:

  • A study is investigating whether Rivaroxaban can help prevent blood clots in people with a high number of irregular heartbeats but who haven’t been diagnosed with atrial fibrillation[1].
  • Another study is looking at the use of Rivaroxaban in patients with rheumatic heart disease and atrial fibrillation[8].
  • Researchers are also studying Rivaroxaban as a potential treatment for a condition called heparin-induced thrombocytopenia, a rare but serious complication of heparin treatment[9].

These ongoing studies may lead to new uses for Rivaroxaban in the future, potentially helping even more patients manage their risk of blood clots[10].

Aspect Details
Main Uses Stroke prevention in atrial fibrillation, treatment of peripheral artery disease, potential use in heparin-induced thrombocytopenia
Dosages Studied 10 mg, 15 mg, 20 mg (may vary based on condition and patient factors)
Key Outcomes Measured Stroke occurrence, systemic embolism, major bleeding events, changes in walking distance (for PAD), time to platelet recovery (for HIT)
Comparators Vitamin K antagonists (e.g. warfarin), aspirin, placebo
Safety Monitoring Bleeding events, cardiovascular events, changes in vital signs and lab values
Special Populations Studies in Chinese volunteers, patients with renal impairment, elderly patients
Unique Features Oral administration, no routine blood monitoring required, potential for fixed dosing

FAQ

  • What is rivaroxaban used for? Rivaroxaban is primarily used to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation. It's also being studied for use in peripheral artery disease and heparin-induced thrombocytopenia.
  • How does rivaroxaban work? Rivaroxaban works by directly inhibiting Factor Xa, an enzyme involved in blood clotting. This helps prevent the formation of blood clots.
  • What dosages of rivaroxaban are being studied? Various dosages are being studied, including 10 mg, 15 mg, and 20 mg. The appropriate dose may depend on factors like kidney function and the specific condition being treated.
  • Are there any side effects associated with rivaroxaban? The main side effect of concern is bleeding. Clinical trials are monitoring for major bleeding events, as well as other adverse effects like changes in blood pressure or abnormal heart rhythms.
  • How does rivaroxaban compare to other blood thinners? Some trials are comparing rivaroxaban to traditional blood thinners like vitamin K antagonists (e.g. warfarin). Researchers are investigating if rivaroxaban is as effective while potentially being easier to use and requiring less monitoring.

Ongoing Clinical Trials on Rivaroxaban

  • Study on Genotype-Guided Treatment with Carbasalate Calcium, Telmisartan, and Rivaroxaban for Patients with Peripheral Arterial Disease

    Not recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study of Rivaroxaban versus standard care in patients with excessive atrial ectopy or short atrial runs who have high risk of blood clots

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Apixaban, Acetylsalicylic Acid, and Rivaroxaban on Heart Valve Thickening in Patients with Aortic Valve Replacement

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Germany

  • Study on the Safety and Tolerability of Abelacimab Compared to Rivaroxaban in Patients with Atrial Fibrillation

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Hungary Poland

  • Study on Rivaroxaban for Patients with Atrial Fibrillation and Coronary Artery Disease After Heart Procedure

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Rivaroxaban, Dabigatran Etexilate, and Fluindione for Patients with Intra-Cardiac Thrombus

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Andexanet Alfa for Patients on Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Needing Urgent Surgery to Reduce Bleeding Risk

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +13

  • Study on Dabigatran, Apixaban, Rivaroxaban, and Edoxaban for Patients with Atrial Fibrillation, Deep Vein Thrombosis, or Pulmonary Embolism

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study Comparing Bleeding Risk of Rivaroxaban and Apixaban in Patients with Acute Venous Thromboembolism

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Ireland

Glossary

  • Atrial Fibrillation: An irregular and often rapid heart rhythm that can increase the risk of stroke and other heart-related complications.
  • Peripheral Artery Disease (PAD): A circulatory condition in which narrowed arteries reduce blood flow to the limbs, often causing leg pain when walking.
  • Heparin-Induced Thrombocytopenia (HIT): A condition where the immune system mistakenly attacks platelets in response to heparin treatment, potentially causing dangerous blood clots.
  • Factor Xa: An enzyme in the blood coagulation system that plays a crucial role in the formation of blood clots.
  • Bioequivalence: The property of two drug products having the same biological effect and availability in the body.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Intermittent Claudication: Pain or discomfort in the legs that occurs during walking or exercise and is relieved by rest, often associated with peripheral artery disease.
  • Systemic Embolism: A blood clot that forms in one part of the body and travels through the bloodstream to lodge in another part.
  • CHA2DS2-VASc Score: A clinical prediction tool for estimating the risk of stroke in patients with atrial fibrillation.
  • International Normalized Ratio (INR): A laboratory test used to measure the blood's tendency to clot and monitor the effects of anticoagulant medications.

References

  1. https://clinicaltrials.eu/trial/study-on-rivaroxaban-for-patients-with-excessive-atrial-ectopy-or-short-atrial-runs-at-high-risk-of-embolism/
  2. https://clinicaltrials.gov/study/NCT02262676
  3. https://clinicaltrials.gov/study/NCT04424381
  4. https://clinicaltrials.gov/study/NCT02537457
  5. https://clinicaltrials.gov/study/NCT02537405
  6. https://clinicaltrials.gov/study/NCT04305028
  7. https://clinicaltrials.gov/study/NCT06187311
  8. https://clinicaltrials.gov/study/NCT02832544
  9. https://clinicaltrials.gov/study/NCT01598168
  10. https://clinicaltrials.gov/study/NCT02273700